Cyclogyl shortage, retinitis pigmentosa designation lead August news


August 22, 2021

1 min read

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

Articles discussing a Cyclogyl shortage and an FDA orphan drug designation for a retinitis pigmentosa treatment lead Healio/OSN coverage so far in August.

Read some of the month’s best-performing items below.

Round table: Board members address Cyclogyl shortage, pediatric myopia

Cyclopentolate is a key ingredient in Cyclogyl, an ophthalmic solution used for cycloplegic refraction during an eye examination. It is also currently in short supply, according to the FDA. Read more.

FDA grants orphan drug designation to ADX-2191 for retinitis pigmentosa

The FDA has granted orphan drug designation to ADX-2191 for the treatment of retinitis pigmentosa, according to a press release from Aldeyra Therapeutics. Read more.

Slightly inferior visual acuity seen with immediate vs. delayed bilateral cataract surgery

A large cohort study based on the IRIS Registry found that immediately sequential bilateral cataract surgery was associated with worse visual outcomes as compared with delayed sequential bilateral cataract surgery. Read more.

Bevacizumab-vikg meets endpoints in phase 3 wet AMD trial

ONS-5010 demonstrated statistically significant results in the treatment of patients with wet age-related macular degeneration, according to a press release from Outlook Therapeutics. Read more.

AAO speaks out on untested biosimilar use in eyes during Avastin supply disruption

The American Academy of Ophthalmology has asked CMS and HHS to prohibit Medicare Advantage and exchange plans from suggesting biosimilar alternatives to Avastin. Read more.


Source link

Elena Johaness

Leave a Reply

Your email address will not be published. Required fields are marked *